Evident has formally completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems specializing in spinning disk confocal and super-resolution microscopy. The strategic acquisition significantly expands Evident’s life science portfolio while strengthening its high-speed, high-content 3D imaging capabilities tailored for life science research, pharmaceutical development, and biotechnology applications.
Established in 2011, CrestOptics develops spinning disk confocal microscopes and structured illumination microscopy (SIM) modules that are meant to fit easily into the current microscope systems on the global market. The company’s product line includes X-Light series of spinning disk microscopes, capable of even illumination and precise optical sections over a large field of view; CICERO system, which provides easy access to confocal microscopy for beginners; and DeepSIM – a super-resolution module of Lattice SIM.
Deepening Strategic Synergy in Advanced Microscopy
The acquisition transitions a long-standing partnership into a unified operational footprint. Evident and CrestOptics have collaborated for years, successfully integrating CrestOptics’ proprietary spinning disk technology directly into Evident‘s specialized microscope systems.
Also Read: Renesas Unveils Dual-Side-Cooled 650V GaN Device to Advance 800V AI Data Center Power Architectures
“Researchers are asking harder questions of increasingly complex biological models, and that demands faster, gentler, higher-resolution imaging,” said Wes Pringle, Evident CEO. “Our customers push the limits of science, and our role is to advance the optical technologies that make new discoveries faster and easier than ever. Evident and CrestOptics operate under a shared vision. After partnering with them, it was clear that their mission, their engineering capability, and most importantly their people, complement our own and together we can deliver more complete solutions to the scientists who depend on us.”
“Joining Evident is a natural next step for CrestOptics,” said Renato Giacobbo Scavo, Chief Executive Officer, CrestOptics. “We share a commitment to advancing what microscopy can reveal. With Evident’s global reach, manufacturing strength, and applications expertise, we can accelerate our innovation roadmap and bring our technologies to many more laboratories worldwide. We are grateful to our previous investors, Apposite Capital and Primo Capital, as well as our Chairman, David Martyr, and the board of directors, for their support throughout this journey.”
Operations and Distribution Footprint
Under the terms of the transaction, CrestOptics will retain its operations, research and development center, and manufacturing hub in Rome. To preserve its role as a technology provider across the broader scientific instrument sector, CrestOptics will maintain its existing distribution channels and global OEM partnerships.
